Physician profile
Michael Lloyd Ridner
NPI 1548231723
$6,171.21
in general payments reported to CMS, 2019-2025
29 companies · $1,878 in 2025
The $1,878 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,563 · 2020: $667 · 2021: $828 · 2022: $363 · 2023: $266 · 2024: $606 · 2025: $1,878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,676 · Travel and Lodging: $1,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,675.88 |
| Travel and Lodging | $1,074.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,790.60 | 2019-2025 | |
| Heartflow, INC. | $1,582.43 | 2025 | |
| Amgen INC. | $472.49 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $371.12 | 2019-2023 | Xarelto |
| Pfizer INC. | $316.74 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $193.94 | 2019-2024 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $186.71 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $137.35 | 2019-2024 | Farxiga |
| Gilead Sciences, INC. | $133.91 | 2019 | |
| Cleerly, INC. | $129.55 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.86 | 2019-2024 | Jardiance |
| Abbott Laboratories | $123.87 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $86.79 | 2019-2023 | Evkeeza |
| Otsuka America Pharmaceutical, INC. | $63.27 | 2019 | |
| Bard Peripheral Vascular, INC. | $59.29 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $54.04 | 2021 | |
| Venclose INC. | $51.00 | 2020 | |
| Merck Sharp & Dohme LLC | $50.07 | 2022-2024 | Verquvo |
| Siemens Medical Solutions USA, INC. | $50.01 | 2023-2024 | Naeotom Alpha |
| Chiesi USA, INC. | $29.58 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $27.84 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $21.76 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $21.12 | 2022 | |
| Cardiovascular Systems INC. | $18.98 | 2019 | |
| Biocompatibles, INC. | $17.24 | 2019 | |
| Medtronic Vascular, INC. | $16.05 | 2020 | |
| Lundbeck LLC | $14.95 | 2019 | |
| Boston Scientific Corporation | $12.86 | 2021 | |
| Tactile Systems Technology INC | $12.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ridner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.